Compare MasterCard Inc (MA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs TG Therapeutics Inc — how do they compare? MasterCard Inc trades at $536.29 (market cap $475.63B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: MasterCard Inc is far larger — about 57.6× TG Therapeutics Inc's market cap, and MasterCard Inc pays a 0.65% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MA | TGTX | |
|---|---|---|
Market Cap | $475.63B | $8.26B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $598.96 | $59.06 |
52-Week Low | $471.55 | $26.39 |
Enterprise Value | $486.37B | $8.50B |
Dividend Yield | 0.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $531.96, down 2.83% on the day, but maintains a strong fundamental profile with robust revenue growth, high profit margins, and consistent earnings beats. The stock is supported by a bullish technical outlook, with key support at $532 and resistance at $540. Recent news highlights institutional buying and strategic initiatives in AI and financial inclusion, reinforcing long-term growth prospects.
The outlook for MA remains positive, driven by expanding digital payments and strategic innovation, though investors face risks from payment disruption threats and competitive pressures. With a consensus price target of $637.20 and no sell ratings, Wall Street sentiment is strongly bullish, positioning MA as a core holding for growth-oriented portfolios.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
